Amgen Inc. reports developments across its biotechnology medicines business, including discovery, development, manufacturing and delivery of human therapeutics. Company updates center on a portfolio and pipeline spanning cancer, inflammatory conditions, rare diseases, heart disease, obesity and obesity-related conditions, with named products and programs such as TEPEZZA, Repatha and IMDELLTRA appearing in clinical and commercial announcements.
Recurring news also covers quarterly financial results, non-GAAP performance measures, manufacturing network investments, supply-chain capacity, research collaborations, medical and investor conference presentations, and executive or organizational changes tied to the integration of biology, technology, artificial intelligence and data across Amgen's operations.
Amgen (NASDAQ: AMGN) will present at the BMO Capital Markets 2020 Prescriptions for Success Healthcare Conference on June 23, 2020, at 4:00 p.m. ET. The presentation will be delivered by Elliott Levy, senior vice president of R&D Strategy and Operations. Interested parties can access a live audio stream through the Events Calendar on Amgen's website, with a replay available for 90 days post-event.
Amgen focuses on developing innovative therapies to address unmet medical needs, utilizing advanced human genetics to enhance health outcomes.